ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
6 announcements with these filters
Q1FY27 was muted with flat revenue growth and EBITDA contraction due to higher energy costs and standard revenue reversal accounting. Management maintains double-digit growth targets despite current geopolitical and US-market headwinds.
Advanced Enzyme reported Q1 FY27 revenue of ₹1,898 mn, up 2% YoY, despite a 10% EBITDA decline. Segment performance was mixed, with specialized manufacturing and bio-processing showing strong growth.
Advanced Enzyme reported its highest-ever quarterly and annual revenue for FY26. Management focused on expanding R&D, human healthcare flagship growth, and navigating global supply chain disruptions.
Advanced Enzyme delivered its highest ever quarterly revenue with robust double-digit growth across all segments. However, management remains cautious about global inflationary pressures on energy and logistics costs potentially impacting near-term margins.
Advanced Enzyme reported strong FY26 performance with 17% revenue growth and 30% PAT growth, driven by Human and Animal Nutrition segments and record margins.
Advanced Enzyme reported strong Q4FY26 results with 22% YoY revenue growth and 69% YoY PAT growth. Focus remains on expanding human and animal nutrition segments globally.